Compare ZEUS & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZEUS | AURA |
|---|---|---|
| Founded | 1954 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.6M | 396.8M |
| IPO Year | 1994 | 2021 |
| Metric | ZEUS | AURA |
|---|---|---|
| Price | $45.01 | $6.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $38.00 | $20.20 |
| AVG Volume (30 Days) | 116.5K | ★ 190.9K |
| Earning Date | 10-28-2025 | 11-13-2025 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $1,898,863,000.00 | N/A |
| Revenue This Year | $0.48 | N/A |
| Revenue Next Year | $2.77 | N/A |
| P/E Ratio | $37.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.32 | $4.35 |
| 52 Week High | $45.41 | $8.60 |
| Indicator | ZEUS | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 71.55 | 49.91 |
| Support Level | $42.62 | $5.72 |
| Resistance Level | $45.41 | $6.15 |
| Average True Range (ATR) | 1.60 | 0.27 |
| MACD | 0.19 | -0.06 |
| Stochastic Oscillator | 95.47 | 35.57 |
Olympic Steel Inc provides metals processing and distribution services in the United States. The company operates in three reportable segments; specialty metals flat products, carbon flat products, and tubular and pipe products. It specializes in the processing and distribution of large volumes of carbon, aluminum, and stainless steel flat-rolled sheet, coils, plates, bars, and fabricated parts. The group serves various industries such as industrial machinery and equipment manufacturers, automobile manufacturers and suppliers, and transportation equipment manufacturers. The company generates majority of the revenue from carbon flat products.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.